High-power, Short-duration Radiofrequency Ablation for the Treatment of AF
Author:
Affiliation:
1. Guy’s and St Thomas’ NHS Foundation Trust, London, UK
2. King’s College London, UK
Abstract
High-power, short-duration (HPSD) ablation for the treatment of AF is emerging as an alternative to ablation using conventional ablation generator settings characterised by lower power and longer duration. Although the reported potential advantages of HPSD ablation include less tissue oedema and collateral tissue damage, a reduction in procedural time and superior ablation lesion formation, clinical studies of HPSD ablation validating these observations are limited. One of the main challenges for HPSD ablation has been the inability to adequately assess temperature and lesion formation in real time. Novel catheter designs may improve the accuracy of intra-ablation temperature recording and correspondingly may improve the safety profile of HPSD ablation. Clinical studies of HPSD ablation are on-going and interpretation of the data from these and other studies will be required to ascertain the clinical value of HPSD ablation.
Publisher
Radcliffe Group Ltd
Subject
Physiology (medical),Cardiology and Cardiovascular Medicine
Reference59 articles.
1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults. JAMA 2001;285:2370-5. https://doi.org/10.1001/jama.285.18.2370; PMID: 11343485.
2. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 study. Circulation 2014;129:837-47. https://doi.org/10.1161/CIRCULATIONAHA.113.005119; PMID: 24345399.
3. Stewart S, Murphy N, Walker A, et al. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004;90:286-92. https://doi.org/10.1136/hrt.2002.008748.
4. Haïssaguerre M, Jaïs P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339:659-66. https://doi.org/10.1056/NEJM199809033391003; PMID: 9725923.
5. Verma A. Atrial-fibrillation ablation should be considered first-line therapy for some patients. Curr Opin Cardiol 2008;23:1-8. https://doi.org/10.1097/HCO.0b013e3282f2e27c; PMID: 18281820.
Cited by 42 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Clinical efficiency and safety of high-power short-duration radiofrequency ablation in treatment of patients with atrial fibrillation;Journal of Arrhythmology;2024-08-22
2. General Anesthesia Improves Efficiency of High-Power Short-Duration Catheter Ablation for Atrial Fibrillation: Comparison with Mild Conscious Sedation;Journal of Personalized Medicine;2024-08-16
3. Computer Simulation of Catheter Cryoablation for Pulmonary Vein Isolation;Healthcare;2024-07-30
4. New Insights into Cardiac Ablation;Atrial Fibrillation - Current Management and Practice [Working Title];2024-07-26
5. Long‐term outcome of high‐power ablation guided by ablation index in the treatment of atrial fibrillation;Journal of Arrhythmia;2024-04-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3